A regional hospital network with eight CT scanners assessed cumulative radiation doses over the course of 2020, a year that saw imaging utilization plummet.
The radiotracer 18F-TRX accurately determines which tumors are most likely to respond to targeted therapy, nuclear medicine researchers reported.
Multiple imaging advocates, notably SNMMI, have been calling on the federal agency to update its policies and require amyloid results prior to starting treatment with Aduhelm.
The Society of Nuclear Medicine & Molecular Imaging says such scans are key for diagnosing the disease and will be monitoring the administration's findings.
The agency now recommends Aduhelm only for patients in the early stages of the disease, more closely aligning with the population tested during clinical trials.
German researchers used 68Ga-FAPI PET/CT imaging to analyze 19 patients with pancreatic ductal adenocarcinomas.
Leading experts say there is no clinical evidence the controversial drug can help patients with cerebral amyloid angiopathy, a condition similar to Alzheimer's disease.
Researchers say extravasations should be more closely monitored and reported, while the ACR and SNMMI caution these events are rare and don't require intense scrutiny.
Koch Disruptive Technologies led this series C-5 effort, with others including Fidelity Management & Research Company and Baillie Gifford also chipping in.
The draft document expands payment for certain cardiac and neurologic indications along with SPECT/CT scans, SNMMI announced.
Frank Scholz, PhD, will oversee the Beloit, Wisconsin, firm's Mo-99 expansion efforts and new radioisotope development programs, among other duties.
General Electric's $18 billion healthcare arm anticipates physicians will require more doses of its Vizamyl F18-PET agent, used to diagnose beta-amyloid plaques in the brain.